A Senate deal to end the government shutdown sent the markets soaring to a sharply higher close with the Dow surging 142 points to 26,214. Nasdaq leaped 71 points to 7408.

On the upside

Array BioPharma (Nasdaq: ARRY) reported positive updated results from a Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, binimetinib and cetuximab.

Analysts expect The Medicines Company's (Nasdaq: MDCO) inclisiran to outsell Esperion Therapeutics' (Nasdaq: ESPR) bemepedoic acid.

Abercrombie & Fitch (NYSE: ANF) lifted its fourth quarter revenue outlook due to a strong holiday shopping season.

On the downside

Sanmina (Nasdaq: SANM) that first quarter results will fall short of previous guidance.

PetMed Express (Nasdaq: PETS) reported higher third quarter earnings and revenue that topped analyst estimates but the stock price fell.

II-Vl (Nasdaq: IIVI) introduced its tristimulus colorimeter filters but the stock price fell on concerns that production of the iPhone X will be scaled back.

In the broad market, advancing issues outpaced decliners by a margin of more than 5 to 3 on the NYSE and by more than 4 to 3 on Nasdaq. The broader S&P 500 climbed 22 points to 2,832. Bitcoin collapsed $883 to $10,320.